Drawbacks and Advantages of Continuous BTK Inhibitor Therapy and Overview of Approved Agents

The biennial International Workshop on Chronic Lymphocytic Leukemia^TM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who shared the latest updates in the treatment and management of CLL.

Tune in as we share some key highlights from this year’s meeting. In this podcast, a variety of topics are covered, including the role of continuous BTK inhibitors (BTKis) in CLL, the importance of investigating the biology of Richter’s transformation (RT), and the need to address the underrepresentation of elderly patients in CLL clinical trials. You will hear from several leading experts, including Kerry Rogers, MD, Ohio State University, Columbus, OH, Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd, CLL Society, Inc., Chula Vista, CA, Raul Cordoba, MD, PhD, University Hospital Fundación Jiménez Díaz, Madrid, Spain, and Adam Kittai, MD, Ohio State University, Columbus, OH.

The post iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials appeared first on VJHemOnc.